01490-A: Evaluation of Aurora kinase inhibitors in canine lymphoma in vitro
Grant Status: Closed
Aurora kinases are a very attractive target because of their central role in the regulation of the cell cycle. A number of small-molecule aurora kinase inhibitors have been intensively investigated, and many clinical trials with different aurora kinases inhibitors have been conducted in human medicine. However, there are no published data showing the effect of aurora kinase inhibitors in veterinary medicine. The investigators have successfully detected the protein expression of aurora kinase -A and -B in canine tissue and cells. They also evaluated the mRNA expression of aurora-A and -B in GL-1 and EMA cells to examine the relationship between mRNA and protein expression, and they observed that there is a correlation between protein expression and mRNA expression in canine tissue and cells. In the present study, the investigators evaluated the effect of ZM447439 in canine lymphoma cell lines. Cytotoxic effect of aurora kinase inhibitors was seen in canine malignant cells. Distribution and population change of the cell cycle phase caused by the aurora kinase inhibitors was seen using cell cycle analysis. Finally, apoptosis as the mechanism of cell death was observed. These results indicate that aurora kinase inhibitors would be a very attractive therapeutic agent for canine lymphoma, and further in vivo study is warranted.
Shiomitsu, K., Xia, X., Waite, K., Sehgal, I., & Li, S. (2013). Evaluation of the Aurora Kinase Inhibitor, ZM447439, in Canine Malignant Lymphoid Cells in vitro. Open Journal of Veterinary Medicine, 03(01), 29–38. https://doi.org/10.4236/ojvm.2013.31006
Help Future Generations of Dogs
Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.